Fusion Pharm Stock Cash Flow From Operations
| FSPM Stock | USD 0.0001 0.00 0.00% |
Fusion Pharm fundamentals help investors to digest information that contributes to Fusion Pharm's financial success or failures. It also enables traders to predict the movement of Fusion Stock. The fundamental analysis module provides a way to measure Fusion Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fusion Pharm stock.
Fusion |
Fusion Pharm Company Cash Flow From Operations Analysis
Fusion Pharm's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Fusion Pharm Cash Flow From Operations | 239.84 K |
Most of Fusion Pharm's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fusion Pharm is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Fusion Pharm has 239.84 K in Cash Flow From Operations. This is 99.95% lower than that of the Consumer Staples Distribution & Retail sector and significantly higher than that of the Consumer Staples industry. The cash flow from operations for all United States stocks is 99.98% higher than that of the company.
Fusion Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fusion Pharm's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fusion Pharm could also be used in its relative valuation, which is a method of valuing Fusion Pharm by comparing valuation metrics of similar companies.Fusion Pharm is currently under evaluation in cash flow from operations category among its peers.
Fusion Fundamentals
| Return On Asset | -1.38 | |||
| Profit Margin | (1.11) % | |||
| Operating Margin | (1.24) % | |||
| Current Valuation | 294.4 K | |||
| Shares Outstanding | 10.59 M | |||
| Price To Earning | (0.07) X | |||
| Price To Sales | 0 X | |||
| Revenue | 594.4 K | |||
| Gross Profit | 34.19 K | |||
| Net Income | (42.08 K) | |||
| Cash And Equivalents | 1.45 K | |||
| Total Debt | 1.2 K | |||
| Current Ratio | 0.73 X | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | 239.84 K | |||
| Earnings Per Share | (0.15) X | |||
| Beta | 9.72 | |||
| Market Capitalization | 1.06 K | |||
| Total Asset | 4.04 K | |||
| Retained Earnings | (9.11 K) | |||
| Working Capital | 728 K | |||
| Current Asset | 1.19 M | |||
| Current Liabilities | 459 K | |||
| Net Asset | 4.04 K |
About Fusion Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fusion Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fusion Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fusion Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Fusion Pharm Piotroski F Score and Fusion Pharm Altman Z Score analysis. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion Pharm. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.